  0086-18989305995        sales@mosinterchem.com
You are here: Home / Products-list / Pharmaceutical Chemicals API / Antineoplastic Drugs API / Mitoxantrone CAS 65271-80-9 Dihydroxyanthraquinone

PRODUCTS DETAILS

Mitoxantrone CAS 65271-80-9 Dihydroxyanthraquinone

Place of Origin:Sichuan,China (Mainland)
Brand:MOSINTER
Mol. mass:444.481 g/mol
Formula:C22H28N4O6

  • 65271-80-9
  • MOSINTER
  • 65271-80-9
Product Description

Payment & Shipping Terms

Supply Capacity

Payment Terms:

T/T, WU

Production Capacity:

1000kg/year

Min. Order:

1 Gram

Packing:

according to the customer's requirements 

Means of Transport:

Ocean, Air, Land

Delivery Date:

7 days

 

Miripla

CAS 141977-79-9

Miplatin is a platinum anticancer drug developed by Sumitomo pharmaceutical plant Club of Japan. The specification of freeze-dried powder injection is 70mg / dose. It has a significant effect on the treatment of liver cancer, malignant lymphoma, non-small cell lung cancer, small cell lung cancer and superficial bladder cancer. The mechanism of action is similar to other platinum drugs. It can inhibit the synthesis and replication of DNA and the growth of tumor by producing alkylation complexes and acting on DNA to form cross-linking within and between chains. Animal studies have shown that after TACE, MIPT suspension can be targeted to accumulate in tumor tissue slow-release active ingredients, which has good antitumor effect, and its antitumor activity is better than that of jingsitatin. The clinical study showed that the ratio of TeV in the two groups was 26.5% (22 / 83) and 17.9% (7 / 39), the two-year survival rates were 75.9 and 70.3%, and the three-year survival rates were 58.4% and 48.7%, respectively. Compared with jingsitatin, no hepatic vascular injury (no effect on the second treatment) was found in the group of miplatin, and the irreversible damage (adverse effect on the prognosis) to the hepatobiliary system was reduced, and the safety was better than jingsitatin. Miplatin is a kind of anticancer drug, which is soluble in the fatty acid ethyl ester of papaverine iodide oil and administered in the hepatic artery. It has a high affinity with the fatty acid ethyl ester of papaverine iodide oil, and remains in the tumor site after administration in the hepatic artery. The platinum component in the suspension can be slowly released into the blood or tissue for a long time. The bivalent platinum compound combines with DNA, and inhibits the proliferation of cancer cells by preventing DNA synthesis It improves the anti-cancer effect. Clinical trials show that the product has a good anti-cancer effect in patients who have received this treatment for the first time, or in patients who have received other treatment methods such as hepatectomy.

We can customize according to customer's requirement

if you have any question pls mail us or call us.


PRODUCT INQUIRY
If you would like to have a question then get in touch today, we are ready to assist 24/7.
We welcome your cooperation and we will develop with you.
Factory-direct Connectivity Solutions.
High quality, Competitive Price.
Custom-tailored solutions.
Problem-solving approach.

OUR PRODUCT/SERVICE

MOSINTER GROUP was established in 2004. The main office is located in Ningbo, China. The production are located in Zhejiang Province, Jiangsu Province and Shandong Province in China. Specializing in the production and marketing of chemical products, MOSINTER GROUP has excellent production equipment and a high-performing sales team as well as advanced manufacturing technique, comprehensive quality management system and modernized testing methods.

QUICK LINK

CONTACT INFO

  0086-18989305995
 0086-574-88212215
  sales@mosinterchem.com
  YinXianDaDao 1357, Guangbo Center Office 2003, Ningbo, Zhejiang, China
 forwardcy
 0086-18989305995
 0086-18989305995
Copyright  2020 Mosinter Group Limited All rights reserved.